Lorazepam

Generic Name: Lorazepam

Brand Names: Ativan, Loreev

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₁₀Cl_₂N_₂O_₂

CAS Number: 846-49-1

Unique Ingredient Identifier: O26FZP769L

Background: Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.

Indication: Lorazepam is FDA-approved for the short-term relief of anxiety symptoms related to anxiety disorders and anxiety associated with depressive symptoms such as anxiety-associated insomnia. It is as well used as an anesthesia premedication in adults to relieve anxiety or to produce sedation/amnesia and for the treatment of status epilepticus.

Some off-label indications of lorazepam include rapid tranquilization of an agitated patient, alcohol withdrawal delirium, alcohol withdrawal syndrome, muscle spasms, insomnia, panic disorder, delirium, chemotherapy-associated anticipatory nausea and vomiting, and psychogenic catatonia.

Associated Conditions: Agitation, Alcohol Withdrawal Delirium, Alcohol Withdrawal Syndrome, Anxiety, Anxiety Disorders, Chemotherapy-Induced Nausea and Vomiting, Delirium, Insomnia, Muscle Spasms, Panic Disorder, Psychogenic Catatonia, Status Epilepticus

Associated Therapies: Anesthetic premedication therapy

Clinical Trials

Diphenhydramine, Lorazepam, and Dexamethasone in Treating Nausea and Vomiting Caused By Chemotherapy

Phase 2

Terminated

Conditions: Nausea
Vomiting
Unspecified Childhood Solid Tumor, Protocol Specific

Interventions: Drug: Decadron®
Drug: Benadryl®
Drug: Ativan®
Drug: ondansetron hydrochloride

First Posted Date: 2007-02-01

Last Posted Date: 2014-07-25

Lead Sponsor: University of South Florida

Target Recruit Count: 7

Registration Number: NCT00429702

Locations: 🇺🇸
CHRISTUS Santa Rosa Children's Hospital, San Antonio, Texas, United States
🇺🇸
Arnold Palmer Hospital for Children, Orlando, Florida, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

and more 4 locations

A Study to Investigate the Effects of GW876008 on Brain Activation During Emotional Processing in Healthy Subjects.

Phase 1

Completed

Conditions: Healthy Subjects

First Posted Date: 2007-01-19

Last Posted Date: 2010-10-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 26

Registration Number: NCT00424697

Locations: 🇺🇸
GSK Investigational Site, La Jolla, California, United States

SPECT Investigation Of The NMDA Receptor System In Healthy Volunteers And Patients With Schizophrenia

Phase 1

Terminated

Conditions: Schizophrenia

First Posted Date: 2006-08-15

Last Posted Date: 2016-01-11

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 55

Registration Number: NCT00364429

Locations: 🇪🇸
GSK Investigational Site, Barcelona, Spain

Randomized Trial Comparing 3 Routes of Delivering Lorazepam to Children.

Phase 3

Terminated

Conditions: Convulsions
Status Epilepticus

First Posted Date: 2006-06-22

Last Posted Date: 2012-07-10

Lead Sponsor: Kamuzu University of Health Sciences

Target Recruit Count: 800

Registration Number: NCT00343096

Locations: 🇲🇼
Queen Elizabeth Central Hospital, Paediatric Dept, Box 360, Blantyre, Malawi

Treatment of Alcohol Withdrawal in Hospital Patients

Phase 4

Completed

Conditions: Alcohol Withdrawal Syndrome

Interventions: Drug: Lorazepam (drug)
Drug: Lorazepam

First Posted Date: 2005-11-07

Last Posted Date: 2016-04-11

Lead Sponsor: Virginia Commonwealth University

Target Recruit Count: 183

Registration Number: NCT00249366

Locations: 🇺🇸
Virginia Commonwealth University Medical Center, Richmond, Virginia, United States

Comparing the Treatment of Alcohol Withdrawal Syndrome Using Gabapentin Versus Lorazepam

Phase 2

Completed

Conditions: Alcohol Withdrawal Syndrome(AWS)

First Posted Date: 2005-09-29

Last Posted Date: 2005-09-29

Lead Sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Target Recruit Count: 160

Registration Number: NCT00229125

Locations: 🇺🇸
Medical University of South Carolina - Center for Drug and Alcohol Programs, Charleston, South Carolina, United States

Pharmaco-Economic Study Of Ultiva In Intensive Care Unit(ICU)Subjects

Phase 4

Completed

Conditions: Sedation

First Posted Date: 2005-09-12

Last Posted Date: 2008-10-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 224

Registration Number: NCT00158873

Locations: 🇳🇱
GSK Investigational Site, Zwolle, Netherlands

Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia

Phase 4

Completed

Conditions: Schizophrenia
Psychoses

Interventions: Drug: antipsychotics vs. Lorazepam (Drugs)

First Posted Date: 2005-09-12

Last Posted Date: 2008-01-30

Lead Sponsor: Heinrich-Heine University, Duesseldorf

Target Recruit Count: 71

Registration Number: NCT00159133

Locations: 🇩🇪
German Research Network on Schizophrenia, Department of Psychiatry and Psychotherapy at the Heinrich-Heine-University Düsseldorf, Düsseldorf, North Rhine-Westphalia, Germany